Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

About this update from Vivos Therapeutics, Inc.

LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it intends to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed rights offering pursuant to which the Company would distribute, as a dividend, transferable subscription rights to its shareholders. The Company currently expects to file a registration statement in connection with the proposed rights offering. Subject to and following the SEC declaring the registration statement effective, the Company intends to distribute the rights as a dividend to shareholders as of a proposed record date to be set as the 30th day following the registration statement being declared effective by the SEC. The timing of the proposed rights offering is solely dependent upon the SEC declaring the future registration statement effective, and there can be no assurance as to whether or when effectiveness will occur. Key Terms of the Proposed Rights Offering The foregoing terms are preliminary and indicative only. The final terms of the proposed rights offering, if commenced, will be set forth in the prospectus included in the registration statement. The Company reserves the right to modify any or all of the foregoing terms at any time. Conditions to Completion of the Proposed Rights Offering The proposed rights offering remains subject to a number of conditions, any of which could delay, alter, or prevent its completion. These include, without limitation: (i) the preparation, filing, and the SEC declaring effective a registration statement covering the rights, the underlying shares of common stock, and the subsequent rights; (ii) compliance with applicable rules of any applicable securities exchange, including any shareholder-approval requirements that may apply and the listing of the new securities; (iii) the availability of a sufficient number of authorized but unissued shares of common stock, which may require an amendment to the Company’s certificate of incorporation and a shareholder vote; (iv) all required approvals and authorizations by the Company’s Board of Direc...

View stock analysis, news, and events for Vivos Therapeutics, Inc.